STOCK TITAN

Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Tyra Biosciences, Inc. (TYRA) CEO Todd Harris to present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company focuses on developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology.
Positive
  • None.
Negative
  • None.

CARLSBAD, Calif., Feb. 7, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that Todd Harris, CEO of TYRA, will present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference on Tuesday, February 13, 2024, at 2pm ET. The conference is being held in a virtual format.

A live and archived webcast of the presentation will be available via the For Investors page on the Investor section of the TYRA website. 

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA.

For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad
aconrad@tyra.bio

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-oppenheimers-34th-annual-healthcare-life-sciences-conference-302056590.html

SOURCE Tyra Biosciences

FAQ

When will Todd Harris, CEO of Tyra Biosciences, Inc., present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference?

Todd Harris will present on Tuesday, February 13, 2024, at 2pm ET.

What is the focus of Tyra Biosciences, Inc.?

The company focuses on developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology.

Where can the live and archived webcast of the presentation be accessed?

The webcast will be available on the 'For Investors' page on the Investor section of the TYRA website.

Tyra Biosciences, Inc.

NASDAQ:TYRA

TYRA Rankings

TYRA Latest News

TYRA Stock Data

968.83M
15.63M
5.34%
82.09%
5.38%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CARLSBAD

About TYRA

tyra biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.